Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil

References

• Otsuka. ABILIFY (aripiprazole) tablets, ABILIFY DISCMELT (aripiprazole) orally disintegrating tablets, ABILIFY (aripiprazole) oral solution, ABILIFY (aripiprazole) injection for intramuscular use only. Prescribing information; 2014 Dec [cited 2015 Oct 5]. Available from: www.otsuka-us.com/Documents/Abilify.PI.pdf
   Google Scholar
• Otsuka. ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, for intramuscular use. Prescribing information; 2015 Jul [cited 2015 Oct 5]. Available from: www.otsuka-us.com/products/Documents/Abilify.M.PI.pdf
   Google Scholar
• Alkermes. ARISTADA (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. Prescribing information; 2015 Oct [cited 2015 Oct 5]. Available from: www.alkermes.com/assets/content/files/AristadaPI.pdf
   Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150:281–288.
   PubMed Web of Science ®Google Scholar
• Raoufinia A, Baker RA, Eramo A, et al. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin. 2015;31:583–592.
   PubMed Web of Science ®Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:1254–1260.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617–624.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013;28:171–176.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205:135–144.
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Nakamura J, Fujii Y, et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161:421–428.
   PubMed Web of Science ®Google Scholar
• De Hert M, Eramo A, Landsberg W, et al. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis. Neuropsychiatr Dis Treat. 2015;11:1299–1306.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Baker RA, Eramo A, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophr Res. 2014;159:415–420.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Baker RA, et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies. Clin Schizophr Relat Psychoses. 2015;9(2):79–87.
   PubMedGoogle Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168:498–504.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Raoufinia A, Mallikaarjun S, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin. 2013;29:1241–1251.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013;16:917–925.
   PubMedGoogle Scholar
• Kane JM, Zhao C, Johnson BR, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015;18:145–154.
   PubMed Web of Science ®Google Scholar
• Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ. 2014;17:567–576.
   PubMedGoogle Scholar
• Rohde M, M Rk N, Håkansson AE, et al. Biological conversion of aripiprazole lauroxil - an N-acyloxymethyl aripiprazole prodrug. Results Pharma Sci. 2014;4:19–25.
   PubMedGoogle Scholar
• Turncliff R, Hard M, Du Y, et al. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res. 2014;159:404–410.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76:1085–1090.
   PubMed Web of Science ®Google Scholar
• Hiraoka S, Uchida S, Namiki N. Preparation and characterization of high-content aripiprazole-loaded core-shell structure microsphere for long-release injectable formulation. Chem Pharm Bull (Tokyo). 2014;62:654–660.
   PubMed Web of Science ®Google Scholar
• Nahata T, Saini TR. D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole. Drug Dev Ind Pharm. 2008;34:668–675.
   PubMed Web of Science ®Google Scholar
• Nahata T, Saini TR. Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J Pharm Sci Technol. 2009;63:113–122.
   PubMedGoogle Scholar
• Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117:412–419.
   PubMed Web of Science ®Google Scholar
• Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4:229–237.
   PubMedGoogle Scholar
• Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67:407–411.
   PubMed Web of Science ®Google Scholar
• Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13:767–783.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72:830–839.
   PubMed Web of Science ®Google Scholar
• Janssen. INVEGA TRINZA (paliperidone palmitate) extended-release injectable suspension for intramuscular use. Prescribing information; 2015 May [cited 2015 Oct 5]. Available from: www.janssencns.com/shared/product/invegatrinza/prescribing-information.pdf
   Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
   PubMed Web of Science ®Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917–1928.
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27:879–911.
   PubMed Web of Science ®Google Scholar
• Citrome L. Partial and non-adherence: we need all the help we can get. Int J Clin Pract. 2015;69:1–2.
   PubMed Web of Science ®Google Scholar
• Czobor P, Van Dorn RA, Citrome L, et al. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015;25:1158–1166.
   PubMed Web of Science ®Google Scholar
• Wistedt B. How does the psychiatric patient feel about depot treatment, compulsion or help? Nord J Psychiatry. 1995;49(Suppl. 35):41–46.
   Web of Science ®Google Scholar
• Caroli F, Raymondet P, Izard I, et al. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165–171.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Peng X, Faries D, et al. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry. 2009;9:46.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568–575.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603–609.
   PubMed Web of Science ®Google Scholar
• Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;175:58–62.
   PubMed Web of Science ®Google Scholar
• Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69:720–731.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13:1115–1125.
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127:93–99.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192–213.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74:957–965.
   PubMed Web of Science ®Google Scholar
• Janssen. RISPERDAL CONSTA (risperidone) long-acting injection. Prescribing information; 2014 June [cited 2015 Oct 5]. Available from: www.janssencns.com/shared/product/risperdalconsta/prescribing-information.pdf
   Google Scholar
• Janssen. INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable suspension for intramuscular use. Prescribing information; 2015 June [cited 2015 Oct 5]. Available from: www.janssencns.com/shared/product/invegasustenna/prescribing-information.pdf
   Google Scholar
• Alkermes. Alkermes announces initiation of clinical study of extended durations of aripiprazole lauroxil for treatment of schizophrenia. Press release; 2014 Dec 15 [cited 2015 Oct 5]. Available from: phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-newsArticle_pf&ID=1999280
   Google Scholar
• Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm. 2014;11:1739–1749.
   PubMed Web of Science ®Google Scholar
• Laffont CM, Gomeni R, Zheng B, et al. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014;53:533–543.
   PubMed Web of Science ®Google Scholar